Tepnel launches new molecular services at ICSE
Tepnel Research Products & Services launched at ICSE a host of new molecular services including a GxP quality genotyping service aimed at the clinical/research market.
Tepnel Research Products & Services launched at ICSE a host of new molecular services including a GxP quality genotyping service aimed at the clinical/research market.
The high-throughout genotyping service will utilise Single Nucleotide Polymorphism (SNP) genotyping providing highly specific and reproducible assays using fluorescent markers. The service uses the company's LIMS infrastructure at its new Scottish facility to track and automate the process.
Other offerings include two new services based on Enzyme Linked ImmunoSorbent Assays (ELISA) and 2-D/3-D gel electrophoresis technology which are specifically for companies developing, manufacturing and marketing biopharmaceutical products, and a new immunoassay development service for the pre-clinical and clinical phases of biopharmaceutical drug development.
The ELISA services will be of particular interest to companies who are developing regulatory compliant pre-clinical toxicological studies, phase I-III bio-analytical and pharmacokinetic studies and ICH stability studies for large molecule biopharmaceuticals.
This immunoassay development service will offer development of regulatory compliant monoclonal and polyclonal bioassays that can be routinely used to support pre-clinical and clinical studies. The use of ELISA technology will provide a marked increase in the level of sensitivity required for biopharmaceutical drug products and will also provide support for bio-marker identification, elucidation and anti-drug information. The service will enable high throughput of samples in either 96 or 384 well formats.